APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation


The purpsoe of this study is to determine the relapse-free survival (RFS) benefit from the addition of a maintenance olaparib following completion of chemotherapy in patients with resected pancreatic carcinoma and a pathogenic germline or somatic mutation in BRCA1, BRCA2 or PALB2.


  • Patient must be ≥18 years of age on day of consent.
  • Patient must have an ECOG Performance Status of 0-2.
  • Patient must have a diagnosis of pancreatic cancer and have successfully undergone a curative intent surgical resection and must have no evidence of recurrent disease as determined by the investigator.
  • NOTE: This includes patients with adenocarcinoma, acinarcarcinoma, squamous cell carcinoma adenosquamous and variants thereof. Patients with neuroendocrine tumors are excluded from enrolling.
  • Additonal criteria must be met based on determination by Investigator and study requirements




NCT ID: NCT04858334



You may be eligible for this study if you meet the following criteria:

  • Conditions: pancreatic cancer
  • Age: Between 18 Years - 100 Years
  • Gender: Male or Female
Updated on 20 Nov 2022 . Study ID: TX11539
Please visit our main page to search for other studies you may be interested in. If you need help finding a study or have any questions, please contact us at inhealth@iu.edu

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center